What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2022-03-18 compared with 2021-03-30 · 146 added, 327 removed, 37 unchanged (93% of the section changed)

1 unchanged sentence

Target Group Inc.

(“Target Group”

or “the Company”) was incorporated in the State of Delaware on July 2, 2013, under our original name of River

Run Acquisition Corporation.

On May 5, 2014, we issued 500,000 shares of common stock to Rubin Schindermann and 500,000 shares

of Common Stock to Alexander Starr.

With the issuance of these shares and the redemption of 19,500,000 shares of common stock issued

to our original officers, directors and shareholders, we effected a change of control.

Schindermann and Mr.

became our new officers and directors.

They accepted the resignations of our original founding officers and directors.

May 13, 2014, the Company changed its name to Chess Supersite Corporation.

On July 23, 2014, we acquired certain

assets (“Acquisition”) of Chess Supersite, Inc., a corporation existing under the laws of Ontario, Canada (“Chess

Canada”).

The Acquisition was consummated pursuant to the terms of the Asset Purchase Agreement and the issuance of 5,000,000

shares of our common stock to Chess Canada.

In the Acquisition, we acquired all right, title and interest in and to the properties,

assets, interests and rights of Chess Canada, including the contracts and intellectual property which are related to the business

of developing, operating and maintaining a website focused on the game of chess.

Chess Supersite, Inc.

is under the common

control of Rubin Schindermann and Alexander Starr.

Our original business comprised the operation

of an extensive chess gaming website under the name ChessStars™.

This comprehensive user-friendly web site www.chessstars.com ,

offered a state-of-the-art playing zone, broadcasts of the major tournaments, intuitive mega database, chess skilled contests and

On July 3, 2018, we filed an amendment

in our Certificate of Incorporation to change our name to Target Group Inc.

Effective October 18, 2018, our common stock became

eligible for quotation on the OTCQB platform operated by OTC Markets Group Inc, under the symbol “CBDY”.

Effective December 12, 2018, our

Board of Directors approved the termination of our ChessStars™

online chess playing platform effective

December 31, 2018.

Effective December 7, 2020, we sold the ChessStars™

business to a former director,

Alexander Starr in consideration of Starr’s cancellation of the $60,000 debt owing to him by us.

During the second quarter of 2020, the

global spread of Coronavirus (COVID-19) continued to have a significant impact on the Canadian and global economy and customer

purchasing behavior, while equity markets remained volatile.

However, these factors have not impacted the Company’s operations,

financial results for the year.

(“Target Group” or “the Company”) was incorporated in the State of Delaware on July 2, 2013, under our original name of River Run Acquisition Corporation.

Effective May 13, 2014, the Company changed its name to Chess Supersite Corporation.

On July 3, 2018, we filed an amendment in our Certificate of Incorporation to change our name to Target Group Inc.

Effective October 18, 2018, our common stock became eligible for quotation on the OTCQB platform operated by OTC Markets Group Inc, under the symbol “CBDY”.

Effective December 12, 2018, our Board of Directors approved the termination of our ChessStars™ online chess playing platform effective December 31, 2018.

Effective December 7, 2020, we sold the ChessStars™ business to a former director, Alexander Starr in consideration of Starr’s cancellation of the $60,000 debt owing to him by us.

During the second quarter of 2020, the global spread of Coronavirus (COVID-19) continued to have a significant impact on the Canadian and global economy and customer purchasing behavior, while equity markets remained volatile.

However, these factors have not impacted the Company’s operations, financial results for the year.

Cannabis Business-Canada

We are now engaged in the cultivation,

processing and distribution of curated cannabis products for the adult-use medical and recreational cannabis market in Canada and,

where legalized by state legislation, in the United States.

We believe that there is a shift in the public’s perception of

cannabis from a state of prohibition to a state of legalization.

In October 2018, Canada became the first major industrialized

nation to legalize adult-use cannabis at the national federal level.

We are now engaged in the cultivation, processing and distribution of curated cannabis products for the adult-use medical and recreational cannabis market in Canada and, where legalized by state legislation, in the United States.

We believe that there is a shift in the public’s perception of cannabis from a state of prohibition to a state of legalization.

In October 2018, Canada became the first major industrialized nation to legalize adult-use cannabis at the national federal level.

Cannabis is still heavily regulated.

However, the medical

use of cannabis is now permitted in up to 29 countries and many more countries have reformed, or are considering reforming, their

cannabis uses laws to include the recreational use of cannabis.

In the 2016 publication by Deloitte, Insights

and Opportunities Recreational Marijuana, the project size of the Canadian adult-use market ranged from CDN$4.9 billion to CDN$8.7

billion annually.

In the 2018 publication by Deloitte, A Society in Transition, an Industry Ready to Boom, the projected size of

the Canadian adult-use market in 2019 ranged from CDN$1.8 billion to CDN$4.3 billion.

The Canadian medical cannabis industry experienced

substantial growth since 2014.

However, the medical use of cannabis is now permitted in up to 29 countries and many more countries have reformed, or are considering reforming, their cannabis uses laws to include the recreational use of cannabis.

In the 2016 publication by Deloitte, Insights and Opportunities Recreational Marijuana, the project size of the Canadian adult-use market ranged from CDN$4.9 billion to CDN$8.7 billion annually.

In the 2018 publication by Deloitte, A Society in Transition, an Industry Ready to Boom, the projected size of the Canadian adult-use market in 2019 ranged from CDN$1.8 billion to CDN$4.3 billion.

The Canadian medical cannabis industry experienced substantial growth since 2014.

Health Canada projects the Canadian cannabis market will reach CDN$1.3 billion in annual value by 2024.

We intend to position ourselves with a

core emphasis on co-packaging services to accommodate all consumer-packaged goods required for the sophisticated cannabis market

in Canada and internationally.

We intend to position ourselves with a core emphasis on wholesale & co-packaging services to accommodate all consumer-packaged goods required for the sophisticated cannabis market in Canada and internationally.

This will integrate cannabinoid research, analytical testing, product development and manufacturing.

Our product manufacturing will include,

but will not be limited to the following:

Our product manufacturing will include, but will not be limited to the following:

● Cannabis flower pods for vaporizer use

5 unchanged sentences

● Infused topical products and CBD wellness products.

To take advantage of the opportunity resulting

from the legalization of adult-use cannabis in Canada, we completed several strategic acquisitions and entered into several significant

agreements as follows:

To take advantage of the opportunity resulting from the legalization of adult-use cannabis in Canada, we completed several strategic acquisitions and entered into several significant agreements as follows:

Visava Inc./Canary Rx Inc.

On June 27, 2018, the Company entered

into an Agreement and Plan of Share Exchange (“Exchange Agreement”) with Visava Inc., a private Ontario, Canada corporation

(“Visava”).

Visava owns 100% of Canary Rx Inc , (“Canary”), a Canadian corporation that operates

a 44,000 square foot facility located in Ontario’s Garden Norfolk County for the production of cannabis.

Canary is a Canadian

Licensed Producer under Health Canada’s Cannabis Act (“Bill C-45”).

Canary expects to grow up to 4.5 million

grams of cannabis annually out of its Simcoe facility once it is at full capacity.

The company is now growing premium cannabis

in 5 of its 8 indoor grow rooms with the intent of bringing the remaining 3 rooms online in short order.

Each 2,200 square feet.

room gets up to 5.4 turns annually.

Pursuant to the Exchange Agreement, the

Company issued to the Visava shareholders an aggregate of 25,500,000 shares of the Company’s Common Stock in exchange for

all of the issued and outstanding common stock held by the Visava shareholders.

In addition of its Common Stock, the Company issued

to the Visava shareholders, prorata Common Stock Purchase Warrants to purchase an aggregate of 25,000,000 shares of the Company’s

Common Stock at a price per share of $0.10 for a period of two years following the issuance date of the Warrants.

The transactions

contemplated by the Exchange Agreement closed effective August 2, 2018.

Visava will continue its business operations as a

first-tier wholly-owned subsidiary of the Company with Canary operating as our second-tier subsidiary.

During the quarter ended,

September 30, 2020, all of the warrants expired, none were exercised.

On June 27, 2018, the Company entered into an Agreement and Plan of Share Exchange (“Exchange Agreement”) with Visava Inc., a private Ontario, Canada corporation (“ Visava ”).

Visava owns 100% of Canary Rx Inc, (“ Canary ”), a Canadian corporation that operates a 44,000 square foot facility located in Ontario’s Garden Norfolk County for the production of cannabis.

Canary is a Canadian Licensed Producer under Health Canada’s Cannabis Act (“Bill C-45”).

Canary expects to grow up to 4 million grams of cannabis annually out of its Simcoe facility once it is at full capacity.

The Company is now growing premium cannabis in indoor grow rooms and each 2,200 square feet room gets up to 5.4 turns annually.

Pursuant to the Exchange Agreement, the Company issued to the Visava shareholders an aggregate of 25,500,000 shares of the Company’s Common Stock in exchange for all of the issued and outstanding common stock held by the Visava shareholders.

In addition to its Common Stock, the Company issued to the Visava shareholders, pro rata Common Stock Purchase Warrants to purchase an aggregate of 25,000,000 shares of the Company’s Common Stock at a price per share of $0.10 for a period of two years following the issuance date of the Warrants.

The transactions contemplated by the Exchange Agreement closed effective August 2, 2018.

Visava will continue its business operations as a first-tier wholly-owned subsidiary of the Company with Canary operating as our second-tier subsidiary.

During the year ended, December 31, 2020, all of the warrants expired, none were exercised.

CannaKorp Inc.

Pursuant to the terms of an Agreement and

Plan of Share Exchange dated January 25, 2019 (“Exchange Agreement”) , on March 1, 2019 we completed

the acquisition of Massachusetts –based CannaKorp Inc., a Delaware corporation (“CannaKorp”).

has developed a single-use pre-measured pod and vaporizer system for consumers interested in vaporizing natural herbs, including

The patent-pending system is known as The Wisp™

and Wisp Pods™.

The Wisp™

vaporizer system extracts

the medically beneficial compounds more efficiently while simultaneously offering a much safer and enjoyable experience than other

alternatives.

Under the terms of the Exchange Agreement,

we issued 30,407,712 shares of our common stock to the exchanging CannaKorp shareholders in exchange for 99.8% of the outstanding

common stock held by the CannaKorp shareholders.

Pursuant to the terms of an Agreement and Plan of Share Exchange dated January 25, 2019 (“Exchange Agreement”) , on March 1, 2019, we completed the acquisition of Massachusetts –based CannaKorp Inc., a Delaware corporation (“CannaKorp”).

CannaKorp has developed a single-use pre-measured pod and vaporizer system for consumers interested in vaporizing natural herbs, including cannabis.

The patent-pending system is known as The Wisp™ and Wisp Pods™.

The Wisp™ vaporizer system extracts the medically beneficial compounds more efficiently while simultaneously offering a much safer and more enjoyable experience than other alternatives.

Under the terms of the Exchange Agreement, we issued 30,407,712 shares of our common stock to the exchanging CannaKorp shareholders in exchange for 99.8% of the outstanding common stock held by the CannaKorp shareholders.

CannaKorp will continue to operate as our subsidiary.

During the year ended, December 31, 2021, all of the warrants expired, none were exercised.

Serious Seeds B.V.

Effective December 6, 2018, the Company

and Canary entered into a Distribution, Collaboration and Licensing Agreement (“Agreement”) with Serious Seeds B.V.

(“Serious Seeds”), incorporated in the Netherlands, and Simon Smit (“Smit”), President of Serious Seeds.

Under the Agreement, Canary was appointed the exclusive distributor in Canada and all other legal markets globally of Serious’

proprietary cannabis seed strains and Serious’

cannabis cuttings, dried flowers, extracts and seeds.

In addition, under the

Agreement Canary Rx and Serious will develop certain “Collaborative Products”

defined as cannabis seed strains created

collaboratively using Serious’

intellectual property.

During the term of the Agreement, Canary will own all of the intellectual

property related to the Collaborative Products.

Under the Agreement, Smit has granted Canary

an exclusive license in Canada and all legal markets globally to Serious’

intellectual property including the right to use

the service mark of Serious Seeds and all of the names of Serious’

proprietary cannabis seed strains including but not limited

to Chronic, AK-47, White Russian, Bubble Gum, Kali Mist, Warlock, Double Dutch, Biddy, Early, Motavation and Strawberry-AKeil.

The initial term of the Agreement will be five (5) years and will be automatically renewed for consecutive five (5) terms subject to rights

of termination upon one hundred and eighty (180) days prior notice.

In consideration of the intellectual property rights granted by Smit

to Canary, the Company will issue to Smit 250,000 shares of the Company’s common stock on the effective date of the Agreement.

addition, on the thirteenth (13) month following the effective date of the Agreement of the initial term, the Company will issue to Smit

5,208 shares of common stock and warrants to purchase 200,000 shares of Target common stock at an exercise price of $0.15 per share.

from the fourteenth (14) month following the effective date of the Agreement and continuing through the sixtieth (60) month of the initial

term, the Company will issue Smit 5,208 shares of common stock and warrants to purchase 16,667 shares of Target common stock, each month,

at varying exercise prices ranging from $0.20 to $0.35 per share.

All of the above warrants must be exercised on or before the two (2)

year anniversary date of each of the warrant issuance dates.

In consideration of Canary’s appointment

as Serious’

exclusive distributor in Canada, Canary will pay Serious certain royalties as follows:

Effective December 6, 2018, the Company and Canary entered into a Distribution, Collaboration and Licensing Agreement (“Agreement”) with Serious Seeds B.V.

(“Serious Seeds”), incorporated in the Netherlands, and Simon Smit (“Smit”), President of Serious Seeds.

Under the Agreement, Canary was appointed the exclusive distributor in Canada and all other legal markets globally of Serious’ proprietary cannabis seed strains and Serious’ cannabis cuttings, dried flowers, extracts and seeds.

In addition, under the Agreement Canary Rx and Serious will develop certain “Collaborative Products” defined as cannabis seed strains created collaboratively using Serious’ intellectual property.

During the term of the Agreement, Canary will own all of the intellectual property related to the Collaborative Products.

Under the Agreement, Smit has granted Canary an exclusive license in Canada and all legal markets globally to Serious’ intellectual property including the right to use the service mark of Serious Seeds and all of the names of Serious’ proprietary cannabis seed strains including but not limited to Chronic, AK-47, White Russian, Bubble Gum, Kali Mist, Warlock, Double Dutch, Biddy, Early, Motavation and Strawberry-AKeil.

The initial term of the Agreement will be five (5) years and will be automatically renewed for consecutive five (5) terms subject to rights of termination upon one hundred and eighty (180) days prior notice.

In consideration of the intellectual property rights granted by Smit to Canary, the Company will issue to Smit 250,000 shares of the Company’s common stock on the effective date of the Agreement.

addition, on the thirteenth (13) month following the effective date of the Agreement of the initial term, the Company will issue to Smit 5,208 shares of common stock and warrants to purchase 200,000 shares of Target common stock at an exercise price of $0.15 per share.

Thereafter, from the fourteenth (14) month following the effective date of the Agreement and continuing through the sixtieth (60) month of the initial term, the Company will issue Smit 5,208 shares of common stock and warrants to purchase 16,667 shares of Target common stock, each month, at varying exercise prices ranging from $0.20 to $0.35 per share.

All of the above warrants must be exercised on or before the two (2) year anniversary date of each of the warrant issuance dates.

In consideration of Canary’s appointment as Serious’ exclusive distributor in Canada, Canary will pay Serious certain royalties as follows:

2.00% of gross sales

4 unchanged sentences

3.00% of gross sales

On October 8, 2019, Canary was

granted licenses to cultivate, process and sell cannabis pursuant to the Cannabis Act (Bill C-45).

These Standard Licenses

enable Canary to produce approximately 3,600kg of dried cannabis flower per year.

Canary has curated a bank of 3,500 seeds, comprised

of more than 125 strains, including the entire Serious Seeds collection.

The Company has the capacity to grow 8 different strains

at a time, within the facility’s 8 indoor separate flower rooms.

On October 8, 2019, Canary was granted licenses to cultivate, process and sell cannabis pursuant to the Cannabis Act (Bill C-45).

These Standard Licenses enable Canary to produce approximately 3,600kg of dried cannabis flower per year.

Canary has curated a bank of 3,500 seeds, comprised of more than 125 strains, including the entire Serious Seeds collection.

The Company has the capacity to grow 8 different strains at a time, within the facility’s 8 indoor separate flower rooms.

Cannavolve Inc.

Sales Agency Agreement

Effective December 13, 2018, the Company

appointed Cannavolve Inc., an Ontario, Canada corporation based in Toronto (“Cannavolve”) , under the

terms of a Licensed Producer/Licensed Processor Sales Agency Agreement (“Agency Agreement”) , as the Company’s

exclusive agent in Canada to market and sell the CannaKorp Wisp™

vaporizer, the Serious Seeds™

products and Canary

branded cannabis in the recreational cannabis markets ( collectively the “Products”).

Cannavolve is an

independent recreational cannabis sales and marketing Company established to represent licensed producers and licensed processors

in Canada of cannabis and cannabis accessories.

Effective December 13, 2018, the Company appointed Cannavolve Inc., an Ontario, Canada corporation based in Toronto (“Cannavolve”) , under the terms of a Licensed Producer/Licensed Processor Sales Agency Agreement (“Agency Agreement”) , as the Company’s exclusive agent in Canada to market and sell the CannaKorp Wisp™ vaporizer, the Serious Seeds™ products and Canary branded cannabis in the recreational cannabis markets ( collectively the “Products”).

Cannavolve is an independent recreational cannabis sales and marketing Company established to represent licensed producers and licensed processors in Canada of cannabis and cannabis accessories.

Cannavolve operates in Canada with offices in Halifax, Montreal, Calgary and Vancouver.

Under the Agency Agreement, Cannavolve will be paid a commission of

6% of net sales based on the wholesale prices of the Products.

The initial term of the Agency Agreement is two (2) years from December 13,

2018 subject to a renewal term of two (2) additional years.

In addition to customary termination provisions based upon the material

default of either the Company or Cannavolve, we can terminate the Agency Agreement without cause upon ninety (90) days prior written notice.

The agreement was renewed on December 13, 2020 for additional two (2) years.

Exclusive License

Effective August 8, 2019, the Company

entered into an Exclusive License Agreement (“License Agreement”) with cGreen, Inc., a Delaware corporation (“cGreen”).

The License Agreement granted the Company an exclusive license to manufacture and distribute the patent-pending THC antidote True

in the United States, Europe and the Caribbean.

The term of the license was ten (10) years and four (4) months

from the effective date of August 8, 2019.

In consideration of the license, the Company had to issue 10,000,000 shares of

its common stock as follows:

Under the Agency Agreement, Cannavolve will be paid a commission of 6% of net sales based on the wholesale prices of the Products.

The initial term of the Agency Agreement is two (2) years from December 13, 2018, subject to a renewal term of two (2) additional years.

In addition to customary termination provisions based upon the material default of either the Company or Cannavolve, we can terminate the Agency Agreement without cause upon ninety (90) days prior written notice.

The agreement was renewed on December 13, 2020, for an additional two (2) years.

Exclusive License Agreement

Effective August 8, 2019, the Company entered into an Exclusive License Agreement (“License Agreement”) with cGreen, Inc., a Delaware corporation (“cGreen”).

The License Agreement granted the Company an exclusive license to manufacture and distribute the patent-pending THC antidote True Focus™ in the United States, Europe and the Caribbean.

The term of the license was ten (10) years and four (4) months from the effective date of August 8, 2019.

In consideration of the license, the Company had to issue 10,000,000 shares of its common stock as follows:

(i) 3.500,000 within ten (10) days of the effective date;

(ii) 3,500,000 shares on

January 10, 2020;

(ii) 3,500,000 shares on January 10, 2020;

and (iii) 3,000,000 shares not later than June 10, 2020.

In addition, the Company would have to

pay cGreen royalties of 7% of the net sales of the licensed products and 7% of all sublicensing revenues collected by the Company.

In addition, the Company would have to pay cGreen royalties of 7% of the net sales of the licensed products and 7% of all sublicensing revenues collected by the Company.

The Company would pay cGreen an advance royalty of $300,000.00 within ten (10) days of the effective date;

$300,000.00 on

January 10, 2020;

$300,000.00 on January 10, 2020;

and $400,000.00 on or before June 10, 2020, and $500,000 on or before November 10, 2020.

royalty payments would be credited against the royalties owed by the Company through December 31, 2020.

During the quarter ended December 31,

2019, the intangible asset was written off based on management’s review and evaluation of its recoverability.

During the quarter ended June 30,

2020, the Company was in arbitration with cGreen for the breaches of the terms of the License Agreement, however, through an early

mediation, both companies reached to a settlement agreement to settle the breaches of the contract on July 27, 2020 (“Effective

Date”).

As per the settlement agreement, the License Agreement has been terminated and the Company does not have to issue

the 10 million shares nor pay the outstanding royalty payable in the amount of $1,191,860.

As consideration, the Company paid $130,000

within 30 days of the Effective Date and will pay $100,000 in monthly installments of $10,000 commencing in April 2021 to

All advance royalty payments would be credited against the royalties owed by the Company through December 31, 2020.

During the quarter ended December 31, 2019, the intangible asset was written off based on management’s review and evaluation of its recoverability.

Additionally, during the quarter ended June 30, 2020, the Company was in arbitration with cGreen for the breaches of the terms of the License Agreement, however, through an early mediation, both companies reached a settlement agreement to settle the breaches of the

contract on July 27, 2020 (“Effective Date”).

As per the settlement agreement, the License Agreement has been terminated and the Company does not have to issue the 10 million shares nor pay the outstanding royalty payable in the amount of $1,191,860.

As consideration, the Company paid $130,000 within 30 days of the Effective Date and will pay $100,000 in monthly installments of $10,000 commencing in April 2021 to cGreen.

As of December 31, 2021, the outstanding balance is $10,000 of which $10,000 (December 31, 2020:

$90,000) is current and $nil (December 31, 2020:

$10,000) is non-current.

Nabis Holding Sales Agreement

Effective September 17, 2019, CannaKorp

entered into a Purchase, Licensing and Distribution Agreement (“Agreement”) with Nabis Arizona Property LLC

of Scottsdale, Arizona (“Nabis”) concerning the distribution of CannaKorp’s Wisp ™

Vaporizer and Wisp™

Pods in Arizona.

The term of the Agreement is three (3) years with automatic renewals

for additional one-year periods unless the Agreement is terminated pursuant to its terms.

Nabis is required to pay CannaKorp $45,000

for the equipment needed to manufacture the WISP™

Pods, of which $4,500 will be paid within three (3) calendar

days of Nabis obtaining regulatory approval of its vertically integrated license and the balance of $40,500 within 180 days of

the effective date of the Agreement.

Under the Agreement, Nabis is licensed

to manufacture the WISP™

Pods and to sell the WISP™

Pods in conjunction with the sale of the WISP™

Nabis is required to meet minimum quarterly orders of two hundred (200) WISP™

Vaporizers and five thousand

(5,000) WISP™

Pods cartridges .

Nabis is licensed to sell the WISP™

Vaporizer and the WISP™

Pods to end users in Arizona, excluding Amazon, eBay, Walmart or other multistate/national brick and mortar or online sales.

CannaKorp has granted Nabis a right of first refusal to obtain an exclusive license in Michigan and in Washington for the same

rights granted to Nabis in Arizona.

During the year ended December 31,

2020, the equipment to Nabis has been shipped and the Company has provided Nabis an additional 360 days before invoicing Nabis

for the equipment.

Once when the additional period has passed, the Company will invoice Nabis.

Additionally, the first quarter

of the Nabis agreement minimums were shipped and invoiced (200 Wisp Units and 5000 Pod Assemblies to enable Nabis to manufacture

5000 complete Wisp Pods) for online and retail distribution in the Arizona Market.

Due to financial strain and difficulties

during the pandemic Nabis was forced to restructure their company in its entirety.

This has caused strain on the financial position

of Nabis and has affected their ability to fulfill their commitments in the agreement signed with CannaKorp.

At this time, the

partnership has since been terminated and all of CannaKorp’s CannaMatic machinery has now been sent back to CannaKorp.

As of the date of this report, the Company does not have any operations, employees or corporate offices based in United States.

Effective September 17, 2019, CannaKorp entered into a Purchase, Licensing and Distribution Agreement (“Agreement”) with Nabis Arizona Property LLC of Scottsdale, Arizona (“Nabis”) concerning the distribution of CannaKorp’s Wisp ™ Vaporizer and Wisp™ Pods in Arizona.

The term of the Agreement was three (3) years with automatic renewals for additional one-year periods unless the Agreement was terminated pursuant to its terms.

Nabis was required to pay CannaKorp $45,000 for the equipment needed to manufacture the WISP™ Pods, of which $4,500 was be paid within three (3) calendar days of Nabis obtaining regulatory approval of its vertically integrated license and the balance of $40,500 within 180 days of the effective date of the Agreement.

Under the Agreement, Nabis was licensed to manufacture the WISP™ Pods and to sell the WISP™ Pods in conjunction with the sale of the WISP™ Vaporizer .

Nabis was required to meet minimum quarterly orders of two hundred (200) WISP™ Vaporizers and five thousand (5,000) WISP™ Pods cartridges .

Nabis was licensed to sell the WISP™ Vaporizer and the WISP™ Pods to end users in Arizona, excluding Amazon, eBay, Walmart or other multistate/national brick and mortar or online sales.

CannaKorp had granted Nabis a right of first refusal to obtain an exclusive license in Michigan and Washington for the same rights granted to Nabis in Arizona.

During the year ended December 31, 2020, the equipment to Nabis had been shipped and the Company had provided Nabis an additional 360 days before invoicing Nabis for the equipment.

Once the additional period had passed, the Company was going to invoice Nabis.

Additionally, in the first quarter of the Nabis agreement, minimum quantities were shipped and invoiced (200 Wisp Units and 5000 Pod Assemblies to enable Nabis to manufacture 5000 complete Wisp Pods) for online and retail distribution in the Arizona Market.

Due to financial strain and difficulties during the pandemic, Nabis was forced to restructure its company in its entirety.

This has caused strain on the financial position of Nabis and has affected their ability to fulfill their commitments in the agreement signed with CannaKorp.

At this time, the partnership has since been terminated and all of CannaKorp’s CannaMatic machinery has now been sent back to CannaKorp.

As of the date of this report, the Company (i.e.

Target Group Inc.

and its subsidiaries) does not have any operations, employees or corporate offices based in United States.

Joint Venture Agreement

Effective May 14, 2020, Canary entered

into a Joint Venture Agreement (“Joint Venture”) with 9258159 Canada Inc., a corporation organized under the laws of

the Province of Ontario, Canada (referred to as “Thrive Cannabis”) and 2755757 Ontario Inc., a corporation organized

under the laws of the Province of Ontario, Canada (referred to as “JVCo”).

Canary and Thrive Cannabis each hold 50%

of the voting equity interest in JVC.

Effective May 14, 2020, Canary entered into a Joint Venture Agreement (“Joint Venture”) with 9258159 Canada Inc., a corporation organized under the laws of the Province of Ontario, Canada (referred to as “Thrive Cannabis”) and 2755757 Ontario Inc., a corporation organized under the laws of the Province of Ontario, Canada (referred to as “JVCo”).

Canary and Thrive Cannabis each hold 50% of the voting equity interest in JVC.

The term of the Joint Venture is five (5) years from its effective date of May 14, 2020.

Under the Joint Venture, JVCo is permitted

to use a portion, consisting of seven (7) rooms of Canary’s licensed cannabis cultivation facilities located in Simcoe,

Ontario, Canada ("Licensed Site Portion”) for the purpose of operating and managing the Licensed Site Portion for the

cultivation and process of cannabis pursuant to Canary’s license issued by Health Canada.

During the term of the Joint Venture,

JVCo will be responsible for the administration, operation and management of the Licensed Site Portion and all proceeds from the

sale of the cannabis and related cannabis products cultivated therein will be payable to the JVCo.

In addition, Canary, Thrive Cannabis, and

JVCo entered into a Unanimous Shareholder Agreement dated May 14, 2020 governing the management and administration of the

business of JVCo.

As per the Joint Venture, Canary will provide

the JVCo with a Hard Cost Loan with the maximum amount of $942,480 (CAD $1,200,000).

This loan bears an interest rate of 7% per

annum, matures in 12 months from effective date, and is be secured against the personal property of the JVCo and Thrive will guarantee

one-half (1/2) of the outstanding balance of the loan.

As at December 31, 2020, the loan advanced amounts to $263,109 (CAD

$335,000) and interest income charged for the year ended in amount of $8,074 (CAD $10,280) is included in other income on the consolidated

statement of operations and comprehensive loss and interest receivable in the amount of the same amount is included in receivable

from joint venture on the consolidated balance sheet.

The JVCo will reimburse Canary for certain

expenses incurred by Canary for the cultivation and processing of cannabis products.

As at December 31, 2020, the total eligible

recoverable expenses were $1,123,731 (CAD $1,430,776) leading to a recoverable amount of $1,091,834 (CAD $1,390,163).

recorded sales of $108,930 (CAD $138,694) during the quarter end of December 31, 2020.

The entire revenue was sold to one customer.

The JVCo shall make payments out of the revenues,

net of applicable taxes and expenses (“Net Income”), in accordance with the following order of priority:

First, the payment of recoverable expenses, explained below;

Second, to the repayment of the Hard Cost Loan until repaid in full;

Third, to the repayment of the Soft Costs (costs of services and materials provide by Thrive Cannabis) until repaid in full;

Finally, any remaining Net Income shall be distributed, on a monthly basis, as follows:

For the first two (2) years following execution of this Agreement, Canary shall receive 60% and Thrive Cannabis shall receive 40%;

For the three (3) years following such period, Canary shall receive 57.5% and Thrive shall receive 42.5%.

The net equity of the JVCo as at December 31,

2020 was negative $523,496 (CAD $666,534) resulting in a loss of equity for $261,748 (CAD $333,267).

The JV had liabilities of

$1,363,018 (CAD $1,735,444) and assets of $839,522 (CAD $1,068,910).

CL Investors Debt Purchase and Assignment

On June 15, 2020, the Company, its

first–tier subsidiaries Visava Inc.

(“Visava”) CannaKorp Inc.

(“CannaKorp”), and the Company’s

second-tier subsidiary, Canary Rx Inc.

(“Canary”), entered into a Debt Purchase and Assignment Agreement (“Agreement”)

with CL Investors Inc.

(“CLI”), a corporation organized under the laws of the Province of Ontario, Canada.

was preliminary date of the agreement and the agreement was not finalized until the later date as indicated below.

The CEO of the Company, is the Secretary

of CLI, a director of the Company, is a shareholder of CLI and the brother of CEO, is the President and sole director of CLI therefore

the below loan from CLI is classified under related party transactions.

Pursuant to the Agreement, CLI purchased

from the Company for the sum of $2,277,660, (CAD $2,900,000) a debt obligation owing from Canary to the Company in the principal

balance of $8,325,240 (CAD $10,600,000 (“Canary Debt”)).

Upon receipt of the consideration, the Company loaned the

full sum to Canary under terms of an unsecured, non-interest-bearing promissory note, subject to a covenant by the Company not

to take any collection action so long as the Canary Debt remains unpaid to CLI.

As a condition of the closing of the Agreement,

the terms of the Canary Debt were amended to provide for interest at 5% per annum with a maturity date of 60 months from the date

of the Agreement (“Term”).

Under the Joint Venture, JVCo is permitted to use the rooms of Canary’s licensed cannabis cultivation facilities located in Simcoe, Ontario, Canada ("Licensed Site Portion”) to operate and manage the Licensed Site Portion for the cultivation and process of cannabis pursuant to Canary’s license issued by Health Canada.

During the term of the Joint Venture, JVCo is responsible for the administration, operation and management of the Licensed Site Portion and all proceeds from the sale of the cannabis and related cannabis products cultivated therein are payable to the JVCo.

In addition, Canary, Thrive Cannabis, and JVCo entered into a Unanimous Shareholder Agreement dated May 14, 2020, governing the management and administration of the business of JVCo.

As per the Joint Venture, Canary will provide the JVCo with a Hard Cost Loan with the maximum amount of $946,560 (CAD 1,200,000).

This loan bears an interest rate of 7% per annum, matures in 12 months from the effective date, and is secured against the personal property of the JVCo and Thrive will guarantee one-half (1/2) of the outstanding balance of the loan.

As of December 31, 2020, the loan advanced amounts to $264,248 (CAD 335,000) and interest income charged for the year ended in the amount of $18,497 (CAD 23,450)

is included in other income on the consolidated statement of operations and comprehensive loss and interest receivable in the amount of $26,606 (CAD 33,730) is included in receivable from joint venture on the consolidated balance sheet.

The JVCo will reimburse Canary for certain expenses incurred by Canary for the cultivation and processing of cannabis products.

Below is the table which summarizes the activity of the year:

Year ended December 31,

Cost of goods sold

Operation expenses

Eligible recoverable expenses

Recoverable amount

Loss on equity

Due to reimbursement of an office and general expense during the current quarter ended which had been expensed in the books of Canary in the prior period, therefore, leading to a credit (negative) expense on the consolidated statement of operations and comprehensive loss.

During the year ended December 31, 2021, revenue was sold to ten customers (2020:

The JVCo shall make payments out of the revenues, net of applicable taxes and expenses (“Net Income”), in accordance with the following order of priority:

a) First, the payment of recoverable expenses;

b) Second, to the repayment of the Hard Cost Loan until repaid in full;

c) Third, to the repayment of the Soft Costs (costs of services and materials provided by Thrive Cannabis) until repaid in full;

d) Finally, any remaining Net Income shall be distributed, on a monthly basis, as follows:

(i) For the first two (2) years following the execution of this Agreement, Canary shall receive 60% and Thrive Cannabis shall receive 40%;

(ii) For the three (3) years following such period, Canary shall receive 57.5% and Thrive shall receive 42.5%.

Below is the position of the JVCo as at:

As of December 31,

CL Investors Debt Purchase and Assignment Agreement

On June 15, 2020, the Company, its first-tier subsidiaries Visava Inc.

(“Visava”) CannaKorp Inc.

(“CannaKorp”), and the Company’s second-tier subsidiary, Canary Rx Inc.

(“Canary”), entered into a Debt Purchase and Assignment Agreement (“Agreement”) with CL Investors Inc.

(“CLI”), a corporation organized under the laws of the Province of Ontario, Canada.

June 15th was the preliminary date of the agreement, and the agreement was not finalized until the later date as indicated below.

The CEO of the Company is the Secretary of CLI, a director of the Company, a shareholder of CLI and the brother of the CEO is the President and sole director of CLI therefore the below loan from CLI is classified under related party transactions.

Pursuant to the Agreement, CLI purchased from the Company for the sum of $2,287,520, (CAD 2,900,000) a debt obligation owing from Canary to the Company in the principal balance of $8,361,280 (CAD 10,600,000 (“Canary Debt”)).

Upon receipt of the consideration, the Company loaned the full sum to Canary under terms of an unsecured, non-interest-bearing promissory note, subject to a covenant by the Company not to take any collection action so long as the Canary Debt remains unpaid to CLI.

As of December 31, 2021, $3,944 (CAD 5,000) is still outstanding from CLI which is presented as other receivable on the consolidated balance sheet.

As a condition of the closing of the Agreement, the terms of the Canary Debt were amended to provide for interest at 5% per annum with a maturity date of 60 months from the date of the Agreement (“Term”).

The Canary Debt will be repaid according to the following schedule:

In the first year of the Term, Canary will pay CLI the greater of $887,502 (CAD $1,130,000) and fifty percent (50%) of the Net Revenue (hereinafter defined), provided that where the latter amount exceeds the former amount, Canary will, by the end of such first year, pay CLI no less than the former amount and Canary will, within thirty (30) days following the end of such first year, pay CLI the balance of such amount owing for such first year;

In the second year of the Term, Canary will pay CLI the greater of $1,649,340 (CAD $2,100,000) and fifty percent (50%) of the Net Revenue, by way of twelve (12) consecutive monthly installments payable on the 14th day of each month commencing on August 14, 2021, provided that where the latter amount exceeds the former amount, Canary will, within thirty (30) days following the end of such second year, pay CLI the balance of such amount owing for such second year;

In the third year of the Term, Canary will pay CLI the greater of $2,528,988 (CAD $3,220,000) and fifty percent (50%) of the Net Revenue, by way of twelve (12) consecutive monthly installments payable on the 14th day of each month commencing on August 14, 2022, provided that where the latter amount exceeds the former amount, Canary will, by the end of such third year, pay CLI no less than the former amount and Canary will, within thirty (30) days following the end of such third year, pay CLI the balance of the such payments owing for such third year;

In the fourth year of the Term, Canary will pay CLI the greater of $2,419,032 (CAD $3,080,000) and fifty percent (50%) of the Net Revenue, by way of twelve (12) consecutive monthly installments payable on the 14th day of each month commencing on August 14, 2023, provided that where the latter amount exceeds the former amount, Canary will Canary will, within thirty (30) days following the end of such fourth year, pay CLI the balance of such amount owing for such fourth year;

In the fifth year of the Term, Canary will pay CLI the balance owing under this Note, by way of twelve (12) consecutive monthly installments payable on the 14th day of each month commencing on August 14, 2024 for an amount calculated by dividing twelve (12) into the sum of all amounts owing under this Note at the beginning of the fifth year of the Term on account of Principal and Interest, provided that where there are further amounts owing under this Note at the end of such fifth year, Canary will pay CLI all such further amounts within five (5) days following the end of such fifth year.

For the purposes of this Note, “Net

Revenue”

will mean any and all revenue generated from Canary’s Licensed Facility (hereinafter defined) to which it

is entitled net of applicable taxes and third-party expenses.

The repayment of the Canary Debt, as amended,

is guaranteed by Visava and the Company’s wholly-owned subsidiary CannaKorp Inc.

and secured by (i) a general security

interest in the assets of the Company, Canary, Visava and CannaKorp Inc., respectively;

and (ii) a pledge by the Company of

all of the issued and outstanding common stock of Canary, Visava and CannaKorp Inc.

a) In the first year of the Term, Canary will pay CLI the greater of $891,344 (CAD 1,130,000) and fifty percent (50%) of the Net Revenue (hereinafter defined), provided that where the latter amount exceeds the former amount, Canary will, by the end of such first year, pay CLI no less than the former amount and Canary will, within thirty (30) days following the end of such first year, pay CLI the balance of such amount owing for such first year;

b) In the second year of the Term, Canary will pay CLI the greater of $1,656,480 (CAD 2,100,000) and fifty percent (50%) of the Net Revenue, by way of twelve (12) consecutive monthly installments payable on the 14th day of each month commencing on August 14, 2021, provided that where the latter amount exceeds the former amount, Canary will, within thirty (30) days following the end of such second year, pay CLI the balance of such amount owing for such second year;

c) In the third year of the Term, Canary will pay CLI the greater of $2,539,936 (CAD 3,220,000) and fifty percent (50%) of the Net Revenue, by way of twelve (12) consecutive monthly installments payable on the 14th day of each month commencing on August 14, 2022, provided that where the latter amount exceeds the former amount, Canary will, by the end of such third year, pay CLI no less than the former amount and Canary will, within thirty (30) days following the end of such third year, pay CLI the balance of such payments owing for such third year;

d) In the fourth year of the Term, Canary will pay CLI the greater of $2,429,504 (CAD 3,080,000) and fifty percent (50%) of the Net Revenue, by way of twelve (12) consecutive monthly installments payable on the 14th day of each month commencing on August 14, 2023, provided that where the latter amount exceeds the former amount, Canary will, within thirty (30) days following the end of such fourth year, pay CLI the balance of such amount owing for such fourth year;

e) In the fifth year of the Term, Canary will pay CLI the balance owing under this Note, by way of twelve (12) consecutive monthly installments payable on the 14th day of each month commencing on August 14, 2024, for an amount calculated by dividing twelve (12) into the sum of all amounts owing under this Note at the beginning of the fifth year of the Term on account of Principal and Interest, provided that where there are further amounts owing under this Note at the end of such fifth year, Canary will pay CLI all such further amounts within five (5) days following the end of such fifth year.

For the purposes of this Note, “Net Revenue” will mean any and all revenue generated from Canary’s Licensed Facility (hereinafter defined) to which it is entitled net of applicable taxes and third-party expenses.

The repayment of the Canary Debt, as amended, is guaranteed by Visava and the Company’s wholly-owned subsidiary CannaKorp Inc.

and secured by (i) a general security interest in the assets of the Company, Canary, Visava and CannaKorp Inc., respectively;

and (ii) a pledge by the Company of all of the issued and outstanding common stock of Canary, Visava and CannaKorp Inc.

held by the Company.

In addition to the foregoing

guarantees, security interest and stock pledge, CLI has been granted an option, in lieu of repayment of the amended Canary Debt,

to demand, in its sole and absolute discretion the transfer, assignment and conveyance of 75% of the issued and outstanding capital

stock of Visava and Canary.

Furthermore, the President and sole director

of CLI has been granted an option to acquire the remaining 25% of the issued and outstanding capital stock of Visava and Canary.

Effective August 14, 2020, the Agreement

was amended (“Amendment”) to provide that CLI will purchase from Rubin Schindermann, a director of the Company, 500,000

shares of the Company’s Series A Preferred Stock in consideration of the payment by CLI to Rubin Schindermann of $78,540

(CAD $100,000) and the issuance to Schindermann of 10,000,000 shares of the Company’s common stock.

In consideration of the

foregoing, Mr., Schindermann resigned as a director of the Company and from any and all administrative and executive positions

with the Company’s subsidiaries Visava Inc., Canary Rx Inc.

In addition to the foregoing guarantees, security interest and stock pledge, CLI has been granted an option, in lieu of repayment of the amended Canary Debt, to demand, in its sole and absolute discretion the transfer, assignment and conveyance of 75% of the issued and outstanding capital stock of Visava and Canary.

Furthermore, the President and sole director of CLI has been granted an option to acquire the remaining 25% of the issued and outstanding capital stock of Visava and Canary.

Effective August 14, 2020, the Agreement was amended (“Amendment”) to provide that CLI will purchase from Rubin Schindermann, a director of the Company, 500,000 shares of the Company’s Series A Preferred Stock in consideration of the payment by CLI to Rubin Schindermann of $78,880 (CAD 100,000) and the issuance to Schindermann of 10,000,000 shares of the Company’s common stock.

In consideration of the foregoing, Mr., Schindermann resigned as a director of the Company and from any and all administrative and executive positions with the Company’s subsidiaries Visava Inc., Canary Rx Inc.

and CannaKorp Inc., respectively.

In addition, the Company issued

Common Stock Purchase Warrant for 10,000,000 shares of Target common stock to CLI as consideration for the Agreement.

Note 14 for additional details on warrants.

In addition, the Company issued Common Stock Purchase Warrant for 10,000,000 shares of Target common stock to CLI as consideration for the Agreement.

Refer to Note 17 for additional details on warrants.

The combined impact of both transactions resulted in debt issuance cost of $251,518.

This debt issuance cost will be amortized over the term of the debt on straight line basis.

The transactions contemplated by the Agreement

and the Amendment closed on August 14, 2020.

This debt issuance cost will be amortized over the term of the debt on a straight-line basis.

The transactions contemplated by the Agreement and the Amendment closed on August 14, 2020.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business